Research ArticleDrug Discovery and Translational Medicine
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676
Katarina Varnäs, Anders Juréus, Peter Johnström, Charlotte Ahlgren, Pär Schött, Magnus Schou, Susanne Gruber, Eva Jerning, Jonas Malmborg, Christer Halldin, Lovisa Afzelius and Lars Farde
Journal of Pharmacology and Experimental Therapeutics September 2016, 358 (3) 464-471; DOI: https://doi.org/10.1124/jpet.116.234146
Katarina Varnäs
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Anders Juréus
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Peter Johnström
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Charlotte Ahlgren
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Pär Schött
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Magnus Schou
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Susanne Gruber
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Eva Jerning
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Jonas Malmborg
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Christer Halldin
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Lovisa Afzelius
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Lars Farde
Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J., J.M., L.A.), Sweden
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Use of PET for Confirmation of Multitarget Occupancy
Katarina Varnäs, Anders Juréus, Peter Johnström, Charlotte Ahlgren, Pär Schött, Magnus Schou, Susanne Gruber, Eva Jerning, Jonas Malmborg, Christer Halldin, Lovisa Afzelius and Lars Farde
Journal of Pharmacology and Experimental Therapeutics September 1, 2016, 358 (3) 464-471; DOI: https://doi.org/10.1124/jpet.116.234146
Research ArticleDrug Discovery and Translational Medicine
Use of PET for Confirmation of Multitarget Occupancy
Katarina Varnäs, Anders Juréus, Peter Johnström, Charlotte Ahlgren, Pär Schött, Magnus Schou, Susanne Gruber, Eva Jerning, Jonas Malmborg, Christer Halldin, Lovisa Afzelius and Lars Farde
Journal of Pharmacology and Experimental Therapeutics September 1, 2016, 358 (3) 464-471; DOI: https://doi.org/10.1124/jpet.116.234146
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement